Substitute Bill No. 5225 seeks to enhance regulatory oversight of drug manufacturers and wholesalers in Connecticut, particularly concerning the sale and distribution of drugs intended for capital punishment. The bill prohibits certain licensees from selling or dispensing any drug or device for execution purposes, clarifying that wholesalers and manufacturers do not include retail pharmacies or hospitals unless they are aware that the drugs will be used for capital punishment. It amends Section 21a-70 of the general statutes, updating definitions and registration requirements, and introduces a tiered fee structure for manufacturers' certificates based on the number of licensed pharmacists or qualified chemists employed. The bill also mandates that no certificate will be issued unless the drugs are manufactured under the supervision of a licensed pharmacist or qualified chemist.

Additionally, the bill imposes new reporting requirements for registered manufacturers and wholesalers regarding the distribution of controlled substances, particularly if they cease distribution due to concerns about diversion. It establishes penalties for violations and clarifies the conditions under which manufacturers and wholesalers can sell controlled drugs, emphasizing compliance with public safety standards. The bill also introduces stricter guidelines for pharmacy practices, including the requirement for valid practitioner-patient relationships and the prohibition of dispensing drugs intended for execution. Overall, the legislation aims to strengthen ethical standards and regulatory compliance in the drug manufacturing and distribution sectors, with various provisions set to take effect on October 1, 2026.

Statutes affected:
Raised Bill: 20-613a
GL Joint Favorable Substitute: 20-613a
File No. 186: 20-613a
JUD Joint Favorable: 20-613a